Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(15):1106-1108; doi:10.1093/jnci/95.15.1106
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fintor, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fintor, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

NEWS

Breast Cancer Group Targets ‘Shareholder Activism’ at Avon

Lou Fintor

The first 10% of the full text of this article appears below.

Breast cancer activists are wielding a potentially powerful new tactic to pressure companies into taking a closer look at the chemicals they put in their products: shareholder activism.

Seizing on the growing grassroots movements aimed at better corporate accountability, the San Francisco-based Breast Cancer Action (BCA) has launched a campaign taking on Avon Products Inc. If successful, the international cosmetic giant will be forced to evaluate the feasibility of finding alternatives to their use of estrogenic chemical preservatives known as parabens in at least 82 products.

"We’re doing everything we can to force the company to behave in a way that is consistent with their public claims—that they care about . . . [Full Text of this Article]

Support for Stockholder Proposal

Conflicting Positions on Safety

No Evidence for Risk or Safety


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?